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Abstract: This study was carried out to assess the efficacy and tolerability of the topical 
application of an aqueous extract of Triticum vulgare (TV) in different vehicles (cream, impreg-
nated gauzes, foam, hydrogel, and dressing gel) for the treatment of venous lower leg ulcers. 
Fifty patients were randomized to receive one of the five investigational vehicles. Treatment 
was performed up to complete healing or to a maximum of 29 days. The wound size reduction 
from baseline was the primary efficacy variable, which was measured by means of a noninva-
sive laser scanner instrument for wound assessment. In all groups, apart from the foam group, 
a similar trend toward the reduction of the surface area was observed. The cream showed the 
greatest effect on the mean reduction of the lesion size. At last visit, six ulcers were healed: two 
in the cream group, three in the gauze group, and one in the dressing gel group. In the patients 
treated with the cream, the gauzes, the hydrogel, and the dressing gel, the reduction of lesion 
size was 40%–50%; the reduction was smaller in the foam group. No impact in terms of age on 
the healing process was found. The Total Symptoms Score decreased in all groups during the 
study; a greater efficacy in terms of signs/symptoms was observed in the patients treated with 
the gauzes. In the dressing gel group, one patient had an infection of the wound after 3 weeks 
of treatment and 2 of colonization, leading to a systemic antibiotic treatment. The events were 
judged as nonrelated to the device used. On the basis of the results, it could be argued that the 
medical device may be useful in the treatment of chronic venous ulcers.
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Introduction
Approximately 1% of the Western population suffers from venous leg ulcers;1 they are 
more common among women and in the elderly.2 These figures may be underestimated 
as a result of inadequate assessment, which fails to identify venous ulcers, and as a result 
of underreporting.3 The primary risk factors are old age, obesity, previous leg injuries, 
deep venous thrombosis, and phlebitis.4 Venous leg ulcers are often recurrent, and open 
ulcers can persist from weeks to many years.5 Severe complications include cellulitis, 
osteomyelitis, and malignant change. The refractory nature of these ulcers increases 
the risk of morbidity and mortality and can have a significant impact on patient quality 
of life and on costs.6–9 Compression therapy is the standard care for venous ulcers and 
chronic venous insufficiency;10,11 various types of compression therapy are available.12–14 
Compression reduces edema, improves venous reflux, enhances healing of ulcers, and 
reduces pain. Success rates range from 30% to 60% at 24 weeks and from 70% to 85% 
after 1 year.15 After an ulcer has healed, lifelong maintenance of compression therapy 
correspondence: Marco romanelli
Wound healing research Unit, 
Dermatology Division, Via roma, 
67, 56126 Pisa, italy
Tel +39 050 992 436
Fax +39 050 551 124
email m.romanelli@med.unipi.it 
Journal name: Drug Design, Development and Therapy
Article Designation: Original Research
Year: 2015
Volume: 9
Running head verso: Romanelli et al
Running head recto: Medical devices containing T. vulgare for treating venous leg ulcers 
DOI: http://dx.doi.org/10.2147/DDDT.S82712
Drug Design, Development and Therapy 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2788
romanelli et al
may reduce the risk of recurrence.16 However, adherence 
to the therapy may be limited by pain, amount of exudate, 
dressing change difficulties, and physical limitations, includ-
ing obesity and contact dermatitis.17,18 Dressings are often 
used under compression bandages to promote faster heal-
ing and prevent adherence of the bandage to the ulcer bed. 
A wide range of dressings are available, including hydrocol-
loids, foams, hydrogels, ointments, and simple nonadherent 
dressings.19,20 No definitive evidence exists of a clinically 
significant difference among dressing types.19
A new medical device produced in the pharmaceutical 
forms of cream, soaked gauzes, foam, hydrogel, and dressing 
gel, intended for the topical treatment of cutaneous wounds, 
is currently under development by the manufacturer. The 
device, containing an aqueous extract of Triticum vulgare, 
acts by removing the excess exudate from the wound surface 
and providing a moist, sterile microenvironment, a barrier 
to microorganisms, and thermal insulation. The aim of this 
study was to evaluate the efficacy and the local tolerability 
of the various forms of the medical device in the topical 
treatment of venous leg ulcers and to identify differences in 
the activity – if any – between the various pharmaceutical 
forms. This was a preliminary pilot study conducted on a 
small group of patients.
Methods
Patient population
The study protocol included patients of both sexes aged 
18–85 years, affected by a single venous ulcer of the lower 
limb lasting no more than 6 months. To be eligible for the 
study, the lesion was required to have clinical and instru-
mental signs of venous insufficiency, with the edema capable 
of being controlled by compression and a lesion surface 
area not smaller than 5 cm2 and not greater than 100 cm2. 
Patients with the following conditions at the screening 
had to be excluded from study participation: pregnancy or 
breast-feeding; obstructive chronic arteriopathies involving 
the affected area of the study lesion; concomitant treat-
ment with antibiotics, NSAID, narcotics, corticosteroids, 
antineoplastics, or immunosoppressants; or presence of 
other important medical conditions that may interfere with 
wound healing.
study design and treatments
The study plan included a baseline visit, wherein the patients 
eligible for the study were randomized using the block 
randomization method which is designed to randomize 
subjects into groups that result in equal sample sizes. This 
method is used to ensure a balance in sample size across 
groups over time. Patients were assigned to receive one of 
the following five treatments: cream, soaked gauzes, foam, 
hydrogel, and dressing gel. The soaked gauzes and the dress-
ing gel were applied onto the lesion which had previously 
been cleansed with a sterile saline solution and covered with 
a sterile gauze and a secondary absorbent dressing in the 
case of particularly exuding lesions. A two-layer bandag-
ing system was applied after every dressing change. In the 
patient group treated with the cream, foam, and hydrogel, the 
products were uniformly distributed on a sterile gauze and 
then applied onto the lesion, as with the gauzes. All the study 
devices were applied at the study site every 3 days, starting 
from the baseline visit. When the dressing was replaced, any 
devitalized tissue was removed using a clip or buffer with 
saline solution. Follow-up visits were scheduled at weekly 
intervals of therapy, for a maximal observational period of 
29 days and a maximum of five visits. Leg compression was 
continued through the study. The use of paracetamol (acet-
aminophen, 500 mg tablets) was permitted as a painkiller.
Outcome measures
The reduction from baseline of the ulcer surface area was the 
primary efficacy variable.21 The surface area was measured 
by means of a laser scanner (Shilouette®, Aranz Medical, 
Christchurch, New Zealand). Signs (perilesional erythema, 
bleeding) and symptoms (burning, pain, itching) due to the 
lesion were measured using a 4-point scale (0–3: absent, 
mild, moderate, severe) at each visit, and in each patient 
the scores were added up to obtain the Total Symptoms 
Score (TSS). Other efficacy variables included the presence/
absence of granulation tissue and the use of relief paraceta-
mol. Adverse events were recorded at all times throughout 
the study.
ethics
The study protocol was approved by the reference Ethi-
cal Committee. Informed written consent was signed by 
all participants prior to any study-related procedure 
being started. The study was conducted according to the 
Declaration of Helsinki (Fortaleza) and the Good Clinical 
Practice rules.
statistical analysis
Being a pilot study, a calculation of the sample size was not 
performed. The following elements were considered for data 
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analysis: safety, ie, all randomized patients who received 
at least one application of study devices; intention-to-treat 
(ITT), ie, all patients of the safety population who did not 
violate major inclusion–exclusion criteria; per protocol (PP), 
ie, all patients of the efficacy population who completed the 
study without major violations of study procedures. The anal-
ysis of the primary efficacy variables was planned on both the 
ITT and PP populations, whereas the analysis of secondary 
variables was planned on the ITT population only. Moreover, 
no major protocol deviations were found, and all analyses 
were conducted on the ITT population. All analyses were per-
formed separately inside the treatment groups. The primary 
analysis of efficacy was performed on the reduction of the 
ulcer surface area at last visit compared to baseline. Para-
metric (Student’s paired t-test) and nonparametric (Wilcoxon 
test) methods were used. The interval confidence (IC)
95%
 of 
the mean of differences was calculated at time points follow-
ing the baseline visit. The same methods described for the 
primary efficacy analysis were used for the reduction of the 
TSS compared to baseline. ANOVA was applied to evaluate 
the impact of age on the healing process. The LOCF (last 
observation carried forward) method was adopted for missing 
data. As a consequence of a marked right-skewness of the 
surface area values, in addition to the arithmetic mean, the 
quadratic mean (root mean square, RMS) was calculated at 
the time points as a descriptive statistic.
Results
Patient disposition and baseline 
characteristics
A total of 50 patients were enrolled and randomized to 
receive the assigned treatments (ten patients in each treat-
ment group). All randomized patients entered the safety and 
ITT population. Table 1 shows the demographic and main 
baseline characteristics in the five groups. The mean lowest 
age was found in the hydrogel group, and the highest in the 
dressing gel group. The foam group showed the largest mean 
ulcer size, and the hydrogel group the smallest.
Efficacy
Table 2 shows the differences vs baseline of the ulcer surface 
area throughout the study, as well as the P-values. Figure 1 
shows the ulcer size (quadratic mean) in the groups at the 
study time points.
In all the groups, apart from the foam group, a similar 
trend toward a reduction of the ulcer surface area was 
observed. The cream showed the greatest effect on the mean 
reduction of lesion size. At last visit, six ulcers were healed: 
two in the cream group, three in the gauzes group, and 
one in the dressing gel group. In one patient of the gauzes 
group, the size of the ulcer remained almost unchanged. The 
percentage reduction of the ulcer surface area at last visit is 
shown in Figure 2. In the patients treated with the cream, 
the gauzes, the hydrogel, and the dressing gel, the reduction 
of lesion size was 40%–50%; the reduction was smallest in 
the foam group.
Apparently, age did not significantly influence the heal-
ing process.
The TSS decreased in all groups throughout the study 
(Figure 3): the greatest efficacy on signs/symptoms was 
observed in the patients treated with the gauzes (P-values: 
Student’s t, 0.031; Wilcoxon, 0.023).
The presence of granulation tissue was observed in almost 
all the patients (cream =8, gauzes =8, foam =9, hydrogel =10, 
dressing gel =8).
No patients took paracetamol. None of patients in any 
group required surgical cleaning or debridement of the lesion 
at any time during the study.
safety
In the dressing gel group after 3 weeks of treatment and 2 of 
colonization, one patient showed an infection of the wound, 
Table 1 Demographic and lesion baseline characteristics in the groups (ten patients in each group)
Cream Soaked gauzes Foam Hydrogel Dressing gel
number of females 7 9 6 6 9
age (years) 70±14 73±10 75±14 68±16 80±6
Weight (kg) 86±20 79±14 74±14 84±17 71±20
height (cm) 165±9 165±8 167±7 167±10 164±10
BMi (kg/cm2) 31.5±6.1 28.9±3.3 26.5±4.0 30.5±7.5 26.1±5.0
surface area (cm2) (min–max) 26.1 (5.2–72.5) 27.1 (8.0–68.3) 33.4 (9.8–66.9) 17.3 (5.6–32.2) 22.2 (5.9–43.3)
Tss 2.0 3.9 2.8 1.6 2.2
Note: entries are mean ± standard deviation, unless otherwise stated.
Abbreviations: BMi, body mass index; Tss, Total symptoms score.
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leading to treatment with systemic antibiotics.22 The events 
were judged as nonrelated to the device used.
Discussion
The etiology of venous ulcers is complex and not fully 
understood, but is thought to be due to chronic venous 
hypertension resulting from venous insufficiency caused 
by a deficient calf-muscle pump.23 People presenting with 
venous leg ulcers have venous insufficiency due to problems 
with the calf-muscle pump as a result of venous occlusion or 
incompetence of the valves in the deep, superficial, or perfo-
rating veins.24 Secondary venous insufficiency occurs when 
damage to the valves is caused by an identifiable condition, 
such as deep vein thrombosis.25 Damage to the venous valves 
results in the blood flowing in the inverse direction, pool-
ing of blood in the veins, and exposure of the veins to high 
pressure. Venous hypertension results in localized edema, 
producing localized tissue damage. As a consequence, tis-
sues may fail to heal after even minor trauma, resulting in 
an ulcer. Once a venous ulcer has occurred it often follows 
a cyclical pattern of healing and recurrence. Recurrence 
rates between 45% and 70% at 1 year are reported.26 The 
time to healing can be very long, and a significant number 
of patients do not complete ulcer healing, or do so only after 
many years.27 Compression bandaging has been identified 
as the gold standard in the treatment of venous leg ulcers. 
The compression system is applied in a graduated fashion, 
with the pressure decreasing from the toe to the knee. The 
reduction of venous pressure and edema allows healing of 
the ulcer to occur. The healing rate can vary, depending 
on initial ulcer size and duration; a mean healing rate of 
70% has been reported for recent smaller ulcers,28 while a 
randomized controlled clinical trial that included ulcers of 
various sizes and duration reported a healing rate of 34%.29 
The use of dressing placed over the ulcer prior to the appli-
cation of compression to improve healing is widespread, 
and the number of available products is increasing.30,31 
However, no clear evidence-based efficacy difference exists 
among dressing types; therefore, new products are currently 
under development. The various pharmaceutical forms of 
the medical device evaluated in this study are intended for 
topical treatment of cutaneous lesions of different origin 
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Figure 1 Quadratic mean of ulcer surface area (cm2) in all the groups during the 
study.
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Figure 2 Percentage reduction (vs baseline) of the ulcer surface area at the end of 
the study in all the groups.
Notes: calculations made on quadratic means. The area reduction was smallest in 
the foam group due to a bigger mean ulcers size.
Table 2 Ulcer surface area (cm2): differences vs baseline value through the study
Cream Soaked gauzes Foam Hydrogel Dressing gel
Visit 2 -2.45 (-5.0, +0.1) -3.78 (-9.8, +2.2) -0.77 (-1.6, +0.1) -1.72 (-3.1, -0.4) -3.74 (-7.2, -0.3)
Visit 3 -3.07 (-5.9, -0.3) -5.64 (-12.6, +1.3) -0.67 (-3.1, +1.8) -4.50 (-7.5, -1.5) -3.65 (-6.8, -0.5)
Visit 4 -6.03 (-10.3, -1.8) -5.40 (-12.7, +1.9) -2.25 (-5.7, +1.2) -6.51 (-10.0, -3.0) -6.10 (-10.8, -1.4)
Visit 5 -11.02 (-18.6, -3.4) -5.59 (-12.8, +1.7) -4.9 (-7.4, -0.8) -8.12 (-12.2, -4.1) -6.31 (-10.2, -0.2.4)
Wilcoxon P-value 0.0059 0.16 0.0039 0.0020 0.039
student’s t-test P-value 0.0095 0.11 0.021 0.0014 0.018
Notes: entries are mean and ic95%. Paired tests on initial and final differences.
Abbreviation: IC, interval confidence.
Drug Design, Development and Therapy 2015:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2791
Medical devices containing T. vulgare for treating venous leg ulcers
(wounds, burns, ulcers, etc). In the composition of the 
device, the watery extract of T. vulgare appears, which has 
been proven to improve the healing of superficial damaged 
tissues.32 In a recent study it has been shown to have a pro-
proliferative effect of the fractions ST-98 and K .1,000 in 
NIH-3T3 fibroblasts. Moreover, these fractions formulated 
as cream preparations were effective in in vivo models of 
skin lesion also.33 In this study, we evaluated the effects of 
the medical device as dressing in addition to compression 
in patients suffering from venous leg ulcers. In all groups, 
a reduction in the lesion surface area and clinical signs/
symptoms of the disease was observed. The best results 
were recorded in the patients treated with the cream (two 
ulcers healed), the gauzes (three ulcers healed), and the 
hydrogel; moreover, it cannot be excluded that on a larger 
treatment time-span and/or in selected patients the dress-
ing gel (one ulcer healed) and foam also can show greater 
activity. Indeed, a similar frequency of granulation tissue 
was observed in all groups. Peculiarly, the effects of the 
different pharmaceuticals on the clinical signs/symptoms 
and surface area reduction did not correspond; in fact, the 
greatest effect on surface area was observed in the cream 
and the hydrogel groups, whereas the reduction of TSS was 
more noticeable in the gauzes group. This could be due 
to the higher baseline score in the latter group, but other 
explanations cannot be excluded. No safety concerns arose 
during the study. Some intentional limitations affected the 
study. They were mainly due to the small number of patients 
in the groups, the relatively short period of observation 
(4 weeks), and the absence of a control group. This was a 
pilot study aimed at evaluating the usefulness of the medical 
device in the treatment of venous ulcers and at speculatively 
examining different activities (if any) in the pharmaceutical 
forms. Therefore, a formal sample size calculation was not 
performed and ten patients in each group were judged as an 
adequate number in order to detect activity and possible dif-
ferences in such activity. This seemed reasonable to us, but, 
as a consequence, the significance (P-value) of the statisti-
cal tests should be interpreted very cautiously. The healing 
of venous ulcers usually requires a month-long treatment; 
however, the primary variable of the study was not the time 
to healing, but rather the reduction of the ulcer surface area 
within a fixed time, nevertheless, six ulcers healed. Finally, 
the absence of a control group appeared to be justified by 
the preliminary nature of the study; the results of the study 
may prove to be the starting point for a larger, longer-lasting, 
controlled, randomized clinical trial.
On the basis of the results, it can be argued that the medi-
cal device can be useful in the treatment of chronic venous 
ulcers. Since the device acts as a protective dressing, it may 
have a greater healing effect on acute skin injuries also, such 
as traumatic wounds and superficial burns.
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